Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark Dowling, Anthony Jeffrey, Sergio Farina, Stephen Boyle, Ross MacDonald, Shafqat Inam, Chun Kei Kris Ma, Vinay Vanguru, Nilu Perera, Hamish Scott, Michael Dickinson, John Seymour, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Constantine Tam, Mary Ann Anderson, Philip Thompson

Blood (2025) 146 (Supplement 1): 2779.

https://doi.org/10.1182/blood-2025-2779

Published: 2025

Journal Articles

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

Guilherme Perini, Ahmad Alhuraiji, Mary Ann Anderson, Gilberto Israel Barranco Lampón, Otavio Cesar Carvalho Guimarães Baiocchi, Ahmet Emre Eskazan, Yeow Tee Goh, Wei-Han Huang, Mervat Mattar, Evgeny Nikitin, Stephen Opat, Miguel Pavlovsky, Wei Xu

Blood (2025) 146 (Supplement 1): 7937.

https://doi.org/10.1182/blood-2025-7937

Published: 2025

Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah

Blood (2025) 146 (Supplement 1): 3891.

https://doi.org/10.1182/blood-2025-3891

Published: 2025

Journal Articles

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

Blood (2025) 146 (Supplement 1): 399.

https://doi.org/10.1182/blood-2025-399

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sean McKeague, Thomas Lew, LeiShong Lau, Philip Thompson, Ashley Whitechurch, Dennis Carney, Gemma Reynolds, Piers Blombery, John Seymour, Andrew Roberts, Mary Ann Anderson

Blood (2025) 146 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2025-2130

Published: 2025

Journal Articles

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience

Safia Belbachir, Mark Dowling, Mary Ann Anderson, Shafqat Inam, Christina Brown, Gaurav Sutrave, Allison Barraclough

Blood (2025) 146 (Supplement 1): 7246.

https://doi.org/10.1182/blood-2025-7246

Published: 2025

Journal Articles

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Chan Cheah, Mohamed Shanavas, Julio Chavez, Yanhong Tong, Xiaoyun (Nicole) Li, Prasanna Kumar, Amit Agarwal, Mary Ann Anderson, Nitin Jain

Blood (2025) 146 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2025-1839

Published: 2025

Journal Articles

Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia

Blood (2024) 144 (26): 2748–2761.

https://doi.org/10.1182/blood.2024024341

Published: 2024

Includes: Supplemental data

Journal Articles

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Hamish W Scott, Mark R Dowling, Daniel Garcia, Samantha van der Linde, Nicole O'Leary, Brydon Panozzo, Adrian Minson, James A Kuzich, Aaron Jun Ning Wong, Michael S Hofman, Monique Youl, Belinda Campbell, Michael Patrick Macmanus, Philip A. Thompson, Mary Ann Anderson, John F. Seymour, Michael J Dickinson, Simon J Harrison

Blood (2024) 144 (Supplement 1): 4511.

https://doi.org/10.1182/blood-2024-209767

Published: 2024

Journal Articles

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Jacob D. Soumerai, Chan Y. Cheah, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, Wei Ding, Haiyi Guo, Constantine S. Tam

Blood (2024) 144 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2024-199175

Published: 2024

Journal Articles

Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling

Gemma K Reynolds, Lewis Williams, Mary Ann Anderson, Mark R Dowling, Adrian Minson, Michael J. Dickinson, Karin A Thursky, Simon J Harrison, Monica A Slavin, Marcel Doerflinger, Benjamin W Teh

Blood (2024) 144 (Supplement 1): 7136.

https://doi.org/10.1182/blood-2024-203133

Published: 2024

Journal Articles

Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T

Gemma K Reynolds, Lewis Williams, Mary Ann Anderson, Mark R Dowling, Adrian Minson, Michael J. Dickinson, Karin A Thursky, Simon J Harrison, Monica A Slavin, Marcel Doerflinger, Benjamin W Teh

Blood (2024) 144 (Supplement 1): 7135.

https://doi.org/10.1182/blood-2024-202836

Published: 2024

Journal Articles

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Joanne Elizabeth Davis, Lina HH Le, Mandy Ludford-Menting, Nicholas Holzwart, Sasanka M Handunnetti, Constantine S. Tam, Mary Ann Anderson, David S. Ritchie, Rachel Koldej

Blood (2024) 144 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2024-199866

Published: 2024

Journal Articles

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Victor S. Lin, Sean Harrop, Sean J. McKeague, Rory Bennett, Adrian Minson, Divya V. Somasekharannair, Edward Chew, Cameron Snell, Stephen Lade, Philip A. Thompson, John F. Seymour, Michael J. Dickinson, Mary Ann Anderson

Blood (2024) 144 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2024-207849

Published: 2024

Journal Articles

Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, Carmela Sales, Sam van der Linde, Izanne Roos, Stefanie Roberts, Fiore D'Aprano, Samantha M. Loi, Mark R Dowling, Michael J. Dickinson, Tomas Kalincik, Simon J Harrison, Charles B. Malpas, Mary Ann Anderson

Blood (2024) 144 (Supplement 1): 7240.

https://doi.org/10.1182/blood-2024-202851

Published: 2024

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Infections in Lymphoma Patients Treated with Bispecific Therapies: A Systematic Review and Meta-Analysis

Gemma K Reynolds, Marsali Maclean, Benjamin Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes

Blood (2023) 142 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2023-185138

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia

Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling

Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era

Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Infections in Lymphoma Patients Treated with Bispecific Therapies: A Systematic Review and Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only